Ascendis Pharma ASASND -2.40%37 Receivables Turnover is 1.53 as of Mar. 2026. GuruFocus rates ASND with a GF Score™ of 37/100. The stock has 5 warning signs investors should review. Among 839 Biotechnology companies, Ascendis Pharma AS ranks better than 64.96% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Ascendis Pharma AS's Revenue for the
three
months ended in Mar. 2026 was $285 Mil. Ascendis Pharma AS's average Accounts Receivable for the
three
months ended in Mar. 2026 was $186 Mil.
Hence, Ascendis Pharma AS's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.53.
Ascendis Pharma AS (NAS:ASND) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Ascendis Pharma AS Receivables Turnover Related Terms
Ascendis Pharma AS Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASND vs JAZZ, BBIO, EXEL: Receivables Turnover Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascendis Pharma AS (ASND) has a Receivables Turnover of 1.53 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ascendis Pharma AS and its competitors. According to the industry distribution chart, Ascendis Pharma AS ranks #294 out of 839 companies in the Biotechnology industry, placing it in the top 35%.
Is Ascendis Pharma AS's Receivables Turnover too high?
Ascendis Pharma AS's current Receivables Turnover is 1.53. The Biotechnology industry median Receivables Turnover is 5.27. Ascendis Pharma AS's value of 1.53 is 71% below this industry median. Based on the distribution chart, Ascendis Pharma AS ranks #294 out of 839 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Receivables Turnover compare to JAZZ and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #294 out of 839 companies for Receivables Turnover. This puts Ascendis Pharma AS in the upper half of its industry. The industry median Receivables Turnover is 5.27. Ascendis Pharma AS's value of 1.53 is 71% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Pharma AS's current Receivables Turnover of 1.53 is 71% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ascendis Pharma AS and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current Receivables Turnover is 1.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current Receivables Turnover of 1.53. The current Receivables Turnover is 1.53 and 71% below the Biotechnology industry median of 5.27. Ascendis Pharma AS's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Receivables Turnover is 1.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score
Get the complete analysis for ASND
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASND has been successfully added to your 
